REFERENCES
1. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2:569-79.
2. Meckes DG Jr, Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci U S A 2010;107:20370-5.
3. Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 2013;32:2747-55.
4. der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012;64:676-705.
5. Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol 2021;16:748-59.
6. Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013;12:347-57.
7. Li F, Zhang J, Chen A, et al. Combined transplantation of neural stem cells and bone marrow mesenchymal stem cells promotes neuronal cell survival to alleviate brain damage after cardiac arrest via microRNA-133b incorporated in extracellular vesicles. Aging (Albany NY) 2021;13:262-78.
8. Wu P, Zhang B, Ocansey DKW, Xu W, Qian H. Extracellular vesicles: a bright star of nanomedicine. Biomaterials 2021;269:120467.
9. Liu C, Bayado N, He D, et al. Therapeutic applications of extracellular vesicles for myocardial repair. Front Cardiovasc Med 2021;8:758050.
10. Fan Z, Liu H, Xue Y, et al. Reversing cold tumors to hot: an immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy. Bioact Mater 2021;6:312-25.
11. Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol 2019;14:1084-7.
12. Chen Y, Gao P, Pan W, et al. Polyvalent spherical aptamer engineered macrophages: X-ray-actuated phenotypic transformation for tumor immunotherapy. Chem Sci 2021;12:13817-24.
13. Gao P, Pan W, Li N, Tang B. Fluorescent probes for organelle-targeted bioactive species imaging. Chem Sci 2019;10:6035-71.
14. Wu Y, Zheng J, Zeng Q, Zhang T, Xing D. Light-responsive charge-reversal nanovector for high-efficiency in vivo CRISPR/Cas9 gene editing with controllable location and time. Nano Res 2020;13:2399-406.
15. Wang X, Wang X, Yue Q, et al. Liquid exfoliation of TiN nanodots as novel sonosensitizers for photothermal-enhanced sonodynamic therapy against cancer. Nano Today 2021;39:101170.
16. Zhou L, Pi W, Hao M, et al. An injectable and biodegradable nano-photothermal DNA hydrogel enhances penetration and efficacy of tumor therapy. Biomater Sci 2021;9:4904-21.
17. Lu C, Fan Z, Xing D. Photo-enhancement of macrophage phagocytic activity via Rac1-mediated signaling pathway: implications for bacterial infection. Int J Biochem Cell Biol 2016;78:206-16.
18. Liu Y, Fan Z, Zhou Y, et al. Self-circulating electrochemiluminescence chip for sensitive detection of circulating tumour nucleic acids in blood. Sens Actuators B Chem 2019;301:127088.
19. Zhao Z, Tan Q, Zhan X, et al. Cascaded electrochemiluminescence signal amplifier for the detection of telomerase activity from tumor cells and tissues. Theranostics 2018;8:5625-33.
21. Gao P, Wang M, Wan X, et al. A COF-based anti-interference nanoplatform for intracellular nucleic acid imaging. Chem Commun (Camb) 2020;56:14267-70.
22. Gao P, Wei R, Chen Y, et al. Multicolor covalent organic framework-DNA nanoprobe for fluorescence imaging of biomarkers with different locations in living cells. Anal Chem 2021;93:13734-41.
23. Gao P, Shen X, Liu X, et al. Nucleic acid-gated covalent organic frameworks for cancer-specific imaging and drug release. Anal Chem 2021;93:11751-7.
24. Xu CF, Iqbal S, Shen S, Luo YL, Yang X, Wang J. Development of “CLAN” nanomedicine for nucleic acid therapeutics. Small 2019;15:e1900055.
25. Bonanni A, Ambrosi A, Pumera M. Nucleic acid functionalized graphene for biosensing. Chemistry 2012;18:1668-73.
26. Sacks D, Baxter B, Campbell BCV, et al. From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), European Stroke Organization (ESO), European Stroke Organization (ESO), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO). Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke 2018;13:612-32.
27. Tapsin S, Sun M, Shen Y, et al. Genome-wide identification of natural RNA aptamers in prokaryotes and eukaryotes. Nat Commun 2018;9:1289.
29. Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol 2017;57:61-79.
30. Gefen T, Castro I, Muharemagic D, Puplampu-Dove Y, Patel S, Gilboa E. A TIM-3 oligonucleotide aptamer enhances T cell functions and potentiates tumor immunity in mice. Mol Ther 2017;25:2280-8.
31. Panigaj M, Johnson MB, Ke W, et al. Aptamers as modular components of therapeutic nucleic acid nanotechnology. ACS Nano 2019;13:12301-21.
32. Wang J, Gao T, Luo Y, et al. In vitro selection of a DNA aptamer by cell-SELEX as a molecular probe for cervical cancer recognition and imaging. J Mol Evol 2019;87:72-82.
33. Liu M, Wang Z, Tan T, et al. An aptamer-based probe for molecular subtyping of breast cancer. Theranostics 2018;8:5772-83.
34. Wang L, Lee JY, Gao L, et al. A DNA aptamer for binding and inhibition of DNA methyltransferase 1. Nucleic Acids Res 2019;47:11527-37.
35. Zheng J, Zhao S, Yu X, Huang S, Liu HY. Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth. Theranostics 2017;7:1373-88.
36. Li Y, Peng Y, Tan Y, et al. A new paradigm for artesunate anticancer function: considerably enhancing the cytotoxicity via conjugating artesunate with aptamer. Signal Transduct Target Ther 2021;6:327.
39. Hu Q, Li H, Wang L, Gu H, Fan C. DNA nanotechnology-enabled drug delivery systems. Chem Rev 2019;119:6459-506.
40. Hong F, Zhang F, Liu Y, Yan H. DNA origami: scaffolds for creating higher order structures. Chem Rev 2017;117:12584-640.
41. Jiang Q, Liu S, Liu J, Wang ZG, Ding B. Rationally designed DNA-origami nanomaterials for drug delivery in vivo. Adv Mater 2019;31:e1804785.
42. Ge Z, Guo L, Wu G, et al. DNA origami-enabled engineering of ligand-drug conjugates for targeted drug delivery. Small 2020;16:e1904857.
44. Li S, Jiang Q, Liu S, et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat Biotechnol 2018;36:258-64.
45. Ma W, Zhan Y, Zhang Y, et al. An intelligent DNA nanorobot with in vitro enhanced protein lysosomal degradation of HER2. Nano Lett 2019;19:4505-17.
46. Jiang Q, Song C, Nangreave J, et al. DNA origami as a carrier for circumvention of drug resistance. J Am Chem Soc 2012;134:13396-403.
47. Jiang Q, Xu X, Yin PA, et al. Circularly polarized luminescence of achiral cyanine molecules assembled on DNA templates. J Am Chem Soc 2019;141:9490-4.
48. Ijäs H, Shen B, Heuer-Jungemann A, et al. Unraveling the interaction between doxorubicin and DNA origami nanostructures for customizable chemotherapeutic drug release. Nucleic Acids Res 2021;49:3048-62.
49. Xu T, Yu S, Sun Y, et al. DNA origami frameworks enabled self-protective siRNA delivery for dual enhancement of chemo-photothermal combination therapy. Small 2021;17:e2101780.
50. Wang Z, Song L, Liu Q, et al. A tubular DNA nanodevice as a siRNA/chemo-drug co-delivery vehicle for combined cancer therapy. Angew Chem Int Ed Engl 2021;60:2594-8.
51. Wang ST, Gray MA, Xuan S, et al. DNA origami protection and molecular interfacing through engineered sequence-defined peptoids. Proc Natl Acad Sci U S A 2020;117:6339-48.
52. Liu J, Song L, Liu S, et al. A DNA-based nanocarrier for efficient gene delivery and combined cancer therapy. Nano Lett 2018;18:3328-34.
53. Wu T, Liu J, Liu M, et al. A nanobody-conjugated DNA nanoplatform for targeted platinum-drug delivery. Angew Chem 2019;131:14362-6.
54. Liu X, Xu X, Zhou Y, Zhang N, Jiang W. Multifunctional molecular beacons-modified gold nanoparticle as a nanocarrier for synergistic inhibition and in situ imaging of drug-resistant-related mRNAs in living cells. ACS Appl Mater Interfaces 2019;11:35548-55.
55. Ma Y, Wang Z, Zhang M, et al. A telomerase-specific doxorubicin-releasing molecular beacon for cancer theranostics. Angew Chem Int Ed Engl 2016;55:3304-8.
56. Wang J, Chao J, Liu H, et al. Clamped hybridization chain reactions for the self-assembly of patterned DNA hydrogels. Angew Chem Int Ed Engl 2017;56:2171-5.
57. Zhang J, Guo Y, Pan G, et al. Injectable drug-conjugated DNA hydrogel for local chemotherapy to prevent tumor recurrence. ACS Appl Mater Interfaces 2020;12:21441-9.
59. Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol 2021;16:630-43.
60. Kusano KF, Pola R, Murayama T, et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med 2005;11:1197-204.
61. Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov 2017;16:89-100.
62. Bartok E, Hartmann G. Immune sensing mechanisms that discriminate self from altered self and foreign nucleic acids. Immunity 2020;53:54-77.
63. Deng C, Zhang Q, Jia M, et al. Tumors and their microenvironment dual-targeting chemotherapy with local immune adjuvant therapy for effective antitumor immunity against breast cancer. Adv Sci (Weinh) 2019;6:1801868.
64. Lai C, Duan S, Ye F, et al. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Theranostics 2018;8:1723-39.
65. Moreira D, Adamus T, Zhao X, et al. STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers. Clin Cancer Res 2018;24:5948-62.
66. Charlebois R, Allard B, Allard D, et al. PolyI:C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors. Cancer Res 2017;77:312-9.
67. Sagiv-Barfi I, Czerwinski DK, Levy S, et al. Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med 2018;10:eaan4488.
68. Ni Q, Zhang F, Liu Y, et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv 2020;6:eaaw6071.
69. Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials 2016;111:55-65.
70. Yildirim M, Yildirim TC, Turay N, et al. TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice. Immunol Lett 2021;239:32-41.
71. Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: TLR3 agonists in cancer therapy. Oncoimmunology 2020;9:1771143.
72. Qiu N, Wang G, Wang J, et al. Tumor-associated macrophage and tumor-cell dually transfecting polyplexes for efficient interleukin-12 cancer gene therapy. Adv Mater 2021;33:e2006189.
73. Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med 2019;11:eaaw5680.
74. Qin F, Xia F, Chen H, et al. A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications. Front Cell Dev Biol 2021;9:633776.
75. Ho PP, Lahey LJ, Mourkioti F, et al. Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy. Proc Natl Acad Sci U S A 2018;115:E9182-91.
76. Parks RJ, Gussoni E. Building immune tolerance through DNA vaccination. Proc Natl Acad Sci U S A 2018;115:9652-4.
77. Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 2020;5:11.
78. Espeseth AS, Cejas PJ, Citron MP, et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. NPJ Vaccines 2020;5:16.
79. Van Hoecke L, Verbeke R, Dewitte H, et al. mRNA in cancer immunotherapy: beyond a source of antigen. Mol Cancer 2021;20:48.
80. Heine A, Juranek S, Brossart P. Clinical and immunological effects of mRNA vaccines in malignant diseases. Mol Cancer 2021;20:52.
81. Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer 2021;20:33.
83. Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci 2021;17:1446-60.
84. Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15.
86. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021;397:1725-35.
87. Haas EJ, Angulo FJ, Mclaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819-29.
88. Alberer M, Gnad-vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 2017;390:1511-20.
89. Kojima R, Bojar D, Rizzi G, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment. Nat Commun 2018;9:1305.
90. Yang J, Wu S, Hou L, et al. Therapeutic effects of simultaneous delivery of nerve growth factor mRNA and protein via exosomes on cerebral ischemia. Mol Ther Nucleic Acids 2020;21:512-22.
91. Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J Control Release 2017;266:8-16.
92. Didiot MC, Hall LM, Coles AH, et al. Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol Ther 2016;24:1836-47.
93. Wan Y, Wang L, Zhu C, et al. Aptamer-conjugated extracellular nanovesicles for targeted drug delivery. Cancer Res 2018;78:798-808.
94. Fan Z, Xiao K, Lin J, Liao Y, Huang X. Functionalized DNA enables programming exosomes/vesicles for tumor imaging and therapy. Small 2019;15:e1903761.
95. Wang J, Chen P, Dong Y, et al. Designer exosomes enabling tumor targeted efficient chemo/gene/photothermal therapy. Biomaterials 2021;276:121056.
96. Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J Control Release 2020;318:1-15.
97. Yu G, Jung H, Kang YY, Mok H. Comparative evaluation of cell- and serum-derived exosomes to deliver immune stimulators to lymph nodes. Biomaterials 2018;162:71-81.
98. Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 2017;546:498-503.
99. Zhupanyn P, Ewe A, Büch T, et al. Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo. J Control Release 2020;319:63-76.
100. Lamichhane TN, Jeyaram A, Patel DB, et al. Oncogene knockdown via active loading of small RNAs into extracellular vesicles by sonication. Cell Mol Bioeng 2016;9:315-24.
101. Wang H, He D, Wan K, et al. In situ multiplex detection of serum exosomal microRNAs using an all-in-one biosensor for breast cancer diagnosis. Analyst 2020;145:3289-96.
102. Lee JH, Kim JA, Kwon MH, Kang JY, Rhee WJ. In situ single step detection of exosome microRNA using molecular beacon. Biomaterials 2015;54:116-25.
103. Lin Y, Wu J, Gu W, et al. Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs. Adv Sci (Weinh) 2018;5:1700611.
104. Stremersch S, Vandenbroucke RE, Van Wonterghem E, Hendrix A, De Smedt SC, Raemdonck K. Comparing exosome-like vesicles with liposomes for the functional cellular delivery of small RNAs. J Control Release 2016;232:51-61.
105. Yang X, Xie B, Peng H, et al. Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes. J Control Release 2021;329:454-67.
106. An Y, Jin T, Zhu Y, Zhang F, He P. An ultrasensitive electrochemical aptasensor for the determination of tumor exosomes based on click chemistry. Biosens Bioelectron 2019;142:111503.
107. Smyth T, Petrova K, Payton NM, et al. Surface functionalization of exosomes using click chemistry. Bioconjug Chem 2014;25:1777-84.
108. Wang B, Yao K, Huuskes BM, et al. Mesenchymal stem cells deliver exogenous microRNA-let7c via exosomes to attenuate renal fibrosis. Mol Ther 2016;24:1290-301.
109. Yu X, Bai Y, Han B, et al. Extracellular vesicle-mediated delivery of circDYM alleviates CUS-induced depressive-like behaviours. J Extracell Vesicles 2022;11:e12185.
110. Wang Y, Chen X, Tian B, et al. Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics 2017;7:1360-72.
111. Reshke R, Taylor JA, Savard A, et al. Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone. Nat Biomed Eng 2020;4:52-68.
112. O’Loughlin AJ, Mäger I, de Jong OG, et al. Functional delivery of lipid-conjugated siRNA by extracellular vesicles. Mol Ther 2017;25:1580-7.
113. Biscans A, Haraszti RA, Echeverria D, et al. Hydrophobicity of lipid-conjugated siRNAs predicts productive loading to small extracellular vesicles. Mol Ther 2018;26:1520-8.
114. Zheng Z, Li Z, Xu C, Guo B, Guo P. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Control Release 2019;311-312:43-9.
115. Pi F, Binzel DW, Lee TJ, et al. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 2018;13:82-9.
116. Yang Z, Shi J, Xie J, et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng 2020;4:69-83.
117. Zhang S, Dong Y, Wang Y, et al. Selective encapsulation of therapeutic mRNA in engineered extracellular vesicles by DNA aptamer. Nano Lett 2021;21:8563-70.
118. Sedlik C, Vigneron J, Torrieri-Dramard L, et al. Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms. J Extracell Vesicles 2014;3:24646.
119. Kanada M, Kim BD, Hardy JW, et al. Microvesicle-mediated delivery of minicircle DNA results in effective gene-directed enzyme prodrug cancer therapy. Mol Cancer Ther 2019;18:2331-42.
120. Zou J, Shi M, Liu X, et al. Aptamer-functionalized exosomes: elucidating the cellular uptake mechanism and the potential for cancer-targeted chemotherapy. Anal Chem 2019;91:2425-30.
121. Mathiyalagan P, Sahoo S. Exosomes-based gene therapy for microRNA delivery. Methods Mol Biol 2017;1521:139-52.
122. Guo S, Perets N, Betzer O, et al. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog siRNA repairs complete spinal cord injury. ACS Nano 2019;13:10015-28.
123. Tang J, Cui X, Zhang Z, et al. Injection-free delivery of MSC-derived extracellular vesicles for myocardial infarction therapeutics. Adv Healthc Mater 2021:e2100312.
124. Zhang Y, Xie Y, Hao Z, et al. Umbilical mesenchymal stem cell-derived exosome-encapsulated hydrogels accelerate bone repair by enhancing angiogenesis. ACS Appl Mater Interfaces 2021;13:18472-87.
125. Gang D, Yu CJ, Zhu S, Zhu P, Nasser MI. Application of mesenchymal stem cell-derived exosomes in kidney diseases. Cell Immunol 2021;364:104358.
